Making sure that your patients are screened for cervical cancer is a critical component of their overall health. The new 2020 Quest Diagnostics Health Trends™ retrospective, longitudinal study confirms the value of co-testing in women ages 30 to 65.1
Comprehensive testing from Quest Diagnostics
For more than 50 years, we’ve been committed to providing diagnostic insights that can help you and your patients work together for better health. You can count on Quest for co-testing solutions that give you a more complete picture to help you make more informed decisions. We offer:
Test ordering information
For more information on the following tests, or for a complete list of available tests, click below to visit our test directory.
|Test code||Test name|
|91384||Image-Guided Pap with Age-Based Screening Protocols|
|91385||Image-Guided Pap with Age-Based Screening with CT/NGa|
|91386||Image-Guided Pap with Age-Based Screening with CT/NG, Trichomonasb|
a CT/NG: Chlamydia trachomatis/Neisseria gonorrhoeae
b CT/NG/Trich: Chlamydia trachomatis/Neisseria gonorrhoeae/Trichomonas vaginalis. Panel components can be ordered separately if not using Smart Codes. Chlamydia/Neisseria gonorrhoeae RNA, TMA, Urogenital (11363), Trichomonas vaginalis RNA, Qualitative, TMA, Pap Vial (90521)
Both imaged and non-imaged Pap tests are acceptable under the American College of Obstetricians and Gynecologists (ACOG) recommendations. Non-imaged Paps, as well as additional testing recommended by ACOG, are available at Quest Diagnostics, and may be ordered individually. Go to www.QuestDiagnostics.com/TestCenter for our full test menu.
- Kaufman HW, Alagia DP, Chen Z, Onisko A, Austin RM. Contributions of liquid-based (Papanicolaou) cytology and human papillomavirus testing in co-testing for detection of cervical cancer and precancer in the United States. Am J Clin Pathol. Published online ahead of print. July 8, 2020. doi:10.1093/ajcp/aqaa074